Rhumbline Advisers Avrobio, Inc. Call Options Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVRO
# of Institutions
49Shares Held
28.1MCall Options Held
9KPut Options Held
100-
Atlas Venture Life Science Advisors, LLC4.54MShares$00.73% of portfolio
-
Bml Capital Management, LLC Zionsville, IN4MShares$03.43% of portfolio
-
Adar1 Capital Management, LLC Austin, TX3.95MShares$01.15% of portfolio
-
Verition Fund Management LLC Greenwich, CT1.93MShares$00.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$00.0% of portfolio
About AVROBIO, Inc.
- Ticker AVRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,773,900
- Description
- AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...